|1.||Sax, Paul E: 12 articles (06/2015 - 03/2009)|
|2.||Daar, Eric S: 8 articles (09/2015 - 12/2009)|
|3.||DeJesus, Edwin: 8 articles (06/2015 - 01/2006)|
|4.||De Clercq, Erik: 8 articles (01/2013 - 11/2002)|
|5.||Cheng, Andrew K: 7 articles (06/2015 - 01/2006)|
|6.||Tierney, Camlin: 7 articles (03/2015 - 12/2009)|
|7.||Ha, Belinda: 7 articles (03/2015 - 12/2009)|
|8.||Miller, Michael D: 7 articles (12/2014 - 01/2006)|
|9.||McComsey, Grace A: 6 articles (03/2015 - 06/2011)|
|10.||Kearney, Brian P: 6 articles (04/2014 - 10/2007)|
06/01/2004 - "Emtricitabine is a safe and effective option for HIV-1 infection in adults as part of a multidrug regimen. "
01/09/2006 - "To compare the safety and efficacy of emtricitabine with placebo in patients with HBV, we conducted a randomized (2:1), double-blind study at 34 sites in North America, Asia, and Europe that enrolled adults between November 2000 and July 2002 who had chronic HBV infection but had never been exposed to nucleoside or nucleotide treatment. "
09/01/2005 - "Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine occurred in 23% of patients. "
09/01/2005 - "Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine."
06/01/2002 - "Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection."
|2.||HIV Infections (HIV Infection)
01/01/2005 - "Emtricitabine: a review of its use in the management of HIV infection."
11/01/2004 - "Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection."
05/01/2004 - "Emtricitabine (FTC) for the treatment of HIV infection."
01/01/2003 - "Emtricitabine: an antiretroviral agent for HIV infection."
01/01/2014 - "Emtricitabine (FTC) is used for the treatment of HIV infection and pre-exposure chemoprophylaxis. "
07/01/2005 - "Based on these data, 200 mg emtricitabine once daily was chosen as the optimal dose for future hepatitis B studies."
07/01/2005 - "The aim of this study was to evaluate long term safety and antiviral activity of different doses of emtricitabine given once daily to patients chronically infected with hepatitis B. "
01/01/2003 - "Reproductive and developmental toxicology studies were conducted with emtricitabine, a nucleoside analog in development for treatment of human immunodeficiency virus (HIV) (Phase III) and hepatitis B (HBV) (Phase III) infections. "
01/01/2011 - "Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients."
09/06/2006 - "Two inhibitors of HIV (tenofovir and emtricitabine) may also be used to treat hepatitis B in selected cases. "
|4.||Acquired Immunodeficiency Syndrome (AIDS)
04/01/2012 - "The International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT), formerly Pediatric AIDS Clinical Trials Group (PACTG), study P1026s is a prospective pharmacokinetic study of HIV-infected pregnant women taking antiretrovirals for clinical indications, including a cohort taking emtricitabine 200 mg once daily. "
05/01/2013 - "The molecularly imprinted polymeric microspheres (MIPMs, 3~5 μm), used as high-performance liquid chromatography (HPLC) and solid-phase extraction (SPE) packing materials for anti-AIDS drug emtricitabine (FTC), were synthesized by precipitation polymerization. "
05/01/2013 - "Synthesis and evaluation of molecularly imprinted polymeric microspheres for highly selective extraction of an anti-AIDS drug emtricitabine."
01/01/2014 - "In 2010, the centre for the AIDS Programme of Research in South Africa (CAPRISA)004 and iPrEx trials (microbicide gel containing tenofovir and oral pill containing tenofovir-emtricitabine, respectively) demonstrated that antiretroviral preexposure prophylaxis (PrEP) reduced the risk of HIV acquisition among high-risk individuals. "
03/01/2012 - "A pivotal component in the current drug combination regimens for the treatment of AIDS as well as the ongoing PrEP trials is tenofovir disoproxil fumarate (TDF, Viread®) and its combination with emtricitabine (FTC). "
|5.||Chronic Hepatitis B
09/01/2014 - "This study evaluated the clinical response of rtM204V and rtM204I subpopulations to TDF by comparing their early viral load decay kinetics to wild-type (WT) subpopulations in chronic hepatitis B patients harboring rtM204V/I prior to initiating TDF or emtricitabine (FTC)/TDF therapy. "
01/09/2006 - "A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B."
07/01/2005 - "Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study."
07/01/2005 - "Emtricitabine was well tolerated and demonstrated a potent antiviral response for up to 2 years in patients with chronic hepatitis B infection. "
06/01/2002 - "These results support further clinical development of emtricitabine for the treatment of chronic hepatitis B infection."
|2.||tenofovir disoproxil (Viread)
|9.||lamivudine drug combination abacavir
|1.||Highly Active Antiretroviral Therapy (HAART)